---
document_datetime: 2025-12-02 07:04:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tremelimumab-astrazeneca.html
document_name: tremelimumab-astrazeneca.html
version: success
processing_time: 0.3028755
conversion_datetime: 2025-12-24 08:05:58.517221
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tremelimumab AstraZeneca

[RSS](/en/individual-human-medicine.xml/67650)

##### Withdrawn

This medicine's authorisation has been withdrawn

tremelimumab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tremelimumab AstraZeneca](#news-on)
- [More information on Tremelimumab AstraZeneca](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 6 November 2023, the European Commission withdrew the marketing authorisation for Tremelimumab AstraZeneca (tremelimumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Tremelimumab AstraZeneca was granted marketing authorisation in the EU on 20 February 2023 for the treatment of metastatic non-small cell lung cancer (NSCLC). The marketing authorisation was initially valid for a 5-year period. Tremelimumab AstraZeneca contains the same active substance as Imjudo, which is authorised in the EU to treat metastatic NSCLC and advanced or unresectable hepatocellular carcinoma. The marketing authorisation holder will maintain the marketing authorisation for Imjudo.

The European Public Assessment Report (EPAR) for Tremelimumab AstraZeneca is updated to indicate that the marketing authorisation is no longer valid.

Tremelimumab AstraZeneca : EPAR - Medicine Overview

Reference Number: EMA/3771/2023

English (EN) (199.69 KB - PDF)

**First published:** 04/04/2023

**Last updated:** 22/08/2024

[View](/en/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-634)

български (BG) (264.96 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/bg/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_bg.pdf)

español (ES) (197.6 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/es/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_es.pdf)

čeština (CS) (251.04 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/cs/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_cs.pdf)

dansk (DA) (194.37 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/da/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_da.pdf)

Deutsch (DE) (210.02 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/de/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_de.pdf)

eesti keel (ET) (183.4 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/et/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_et.pdf)

ελληνικά (EL) (284.18 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/el/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_el.pdf)

français (FR) (202.86 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/fr/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_fr.pdf)

hrvatski (HR) (225.77 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/hr/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_hr.pdf)

italiano (IT) (194.48 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/it/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (238.61 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/lv/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (238.03 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/lt/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_lt.pdf)

magyar (HU) (233.61 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/hu/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_hu.pdf)

Malti (MT) (249.61 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/mt/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_mt.pdf)

Nederlands (NL) (211.68 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/nl/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_nl.pdf)

polski (PL) (247.53 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/pl/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_pl.pdf)

português (PT) (196.92 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/pt/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_pt.pdf)

română (RO) (235.83 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/ro/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_ro.pdf)

slovenčina (SK) (246.09 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sk/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_sk.pdf)

slovenščina (SL) (234.1 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sl/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_sl.pdf)

Suomi (FI) (193.92 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/fi/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_fi.pdf)

svenska (SV) (195.71 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sv/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_sv.pdf)

Tremelimumab AstraZeneca : EPAR - Risk Management Plan

English (EN) (2.52 MB - PDF)

**First published:** 04/04/2023

**Last updated:** 22/08/2024

[View](/en/documents/rmp/tremelimumab-astrazeneca-epar-risk-management-plan_en.pdf)

## Product information

Tremelimumab AstraZeneca : EPAR - Product Information

English (EN) (1.11 MB - PDF)

**First published:** 04/04/2023

**Last updated:** 22/08/2024

[View](/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-476)

български (BG) (1.13 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/bg/documents/product-information/tremelimumab-astrazeneca-epar-product-information_bg.pdf)

español (ES) (1.13 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/es/documents/product-information/tremelimumab-astrazeneca-epar-product-information_es.pdf)

čeština (CS) (1.06 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/cs/documents/product-information/tremelimumab-astrazeneca-epar-product-information_cs.pdf)

dansk (DA) (1.09 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/da/documents/product-information/tremelimumab-astrazeneca-epar-product-information_da.pdf)

Deutsch (DE) (1.33 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/de/documents/product-information/tremelimumab-astrazeneca-epar-product-information_de.pdf)

eesti keel (ET) (1.1 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/et/documents/product-information/tremelimumab-astrazeneca-epar-product-information_et.pdf)

ελληνικά (EL) (1.24 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/el/documents/product-information/tremelimumab-astrazeneca-epar-product-information_el.pdf)

français (FR) (1.16 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/fr/documents/product-information/tremelimumab-astrazeneca-epar-product-information_fr.pdf)

hrvatski (HR) (1.08 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/hr/documents/product-information/tremelimumab-astrazeneca-epar-product-information_hr.pdf)

íslenska (IS) (1.1 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/is/documents/product-information/tremelimumab-astrazeneca-epar-product-information_is.pdf)

italiano (IT) (1.09 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/it/documents/product-information/tremelimumab-astrazeneca-epar-product-information_it.pdf)

latviešu valoda (LV) (1.08 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/lv/documents/product-information/tremelimumab-astrazeneca-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.21 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/lt/documents/product-information/tremelimumab-astrazeneca-epar-product-information_lt.pdf)

magyar (HU) (1.21 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/hu/documents/product-information/tremelimumab-astrazeneca-epar-product-information_hu.pdf)

Malti (MT) (1.3 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/mt/documents/product-information/tremelimumab-astrazeneca-epar-product-information_mt.pdf)

Nederlands (NL) (1.15 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/nl/documents/product-information/tremelimumab-astrazeneca-epar-product-information_nl.pdf)

norsk (NO) (1.1 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/no/documents/product-information/tremelimumab-astrazeneca-epar-product-information_no.pdf)

polski (PL) (1.23 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/pl/documents/product-information/tremelimumab-astrazeneca-epar-product-information_pl.pdf)

português (PT) (1.16 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/pt/documents/product-information/tremelimumab-astrazeneca-epar-product-information_pt.pdf)

română (RO) (1.22 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/ro/documents/product-information/tremelimumab-astrazeneca-epar-product-information_ro.pdf)

slovenčina (SK) (1.35 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sk/documents/product-information/tremelimumab-astrazeneca-epar-product-information_sk.pdf)

slovenščina (SL) (1.05 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sl/documents/product-information/tremelimumab-astrazeneca-epar-product-information_sl.pdf)

Suomi (FI) (1.12 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/fi/documents/product-information/tremelimumab-astrazeneca-epar-product-information_fi.pdf)

svenska (SV) (1.06 MB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sv/documents/product-information/tremelimumab-astrazeneca-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG1659 04/09/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tremelimumab AstraZeneca : EPAR - All authorised presentations

English (EN) (58.05 KB - PDF)

**First published:** 04/04/2023

**Last updated:** 22/08/2024

[View](/en/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-603)

български (BG) (59.93 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/bg/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_bg.pdf)

español (ES) (53.28 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/es/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59.01 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/cs/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.09 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/da/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (55.98 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/de/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (53.27 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/et/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (66.29 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/el/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_el.pdf)

français (FR) (56.2 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/fr/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (60.65 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/hr/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (55.46 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/is/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_is.pdf)

italiano (IT) (58.33 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/it/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (58.17 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/lv/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (56.54 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/lt/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (54.08 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/hu/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.46 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/mt/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (55.09 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/nl/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (53.09 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/no/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_no.pdf)

polski (PL) (55.18 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/pl/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_pl.pdf)

português (PT) (55.18 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/pt/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.8 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/ro/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (57.06 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sk/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (53.23 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sl/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (57.15 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/fi/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (57.5 KB - PDF)

**First published:**

04/04/2023

**Last updated:**

22/08/2024

[View](/sv/documents/all-authorised-presentations/tremelimumab-astrazeneca-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tremelimumab AstraZeneca Active substance tremelimumab International non-proprietary name (INN) or common name tremelimumab Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01FX20

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.

## Authorisation details

EMA product number EMEA/H/C/004650 Marketing authorisation holder

AstraZeneca AB

151 85 Sodertalje

Opinion adopted 15/12/2022 Marketing authorisation issued 20/02/2023 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tremelimumab AstraZeneca : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (306.54 KB - PDF)

**First published:** 11/09/2023

**Last updated:** 22/08/2024

[View](/en/documents/procedural-steps-after/tremelimumab-astrazeneca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Tremelimumab AstraZeneca : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/42903/2023

English (EN) (12.83 MB - PDF)

**First published:** 04/04/2023

**Last updated:** 22/08/2024

[View](/en/documents/assessment-report/tremelimumab-astrazeneca-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tremelimumab AstraZeneca

Adopted

Reference Number: EMA/CHMP/925958/2022

English (EN) (176.39 KB - PDF)

**First published:** 16/12/2022

**Last updated:** 22/08/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tremelimumab-astrazeneca_en.pdf)

#### News on Tremelimumab AstraZeneca

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022) 16/12/2022

#### More information on Tremelimumab AstraZeneca

- [EMEA-002029-PIP01-16-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002029-pip01-16-m04)

**This page was last updated on** 22/08/2024

## Share this page

[Back to top](#main-content)